Trials / Recruiting

RecruitingNCT06817161

Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer: the ESTANVO Randomized Trial

Status: Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 116 (estimated)

Sponsor: Centre Francois Baclesse · Academic / Other
Sex: Female
Age: 18 Years
Healthy volunteers: Not accepted

Summary

Detailed description

Impact of stimulation of parasympathetic activity by transcutaneous auricular vagus nerve stimulation (taVNS) on quality of life (QoL) relating to digestive symptoms in patients undergoing first-line treatment for ovarian cancer, as compared to shame taVNS Randomization between: * Experimental group: transcutaneous auricular vagus nerve stimulation (taVNS) * Control group: placebo using the same device that does not deliver electrical stimulation

Conditions

Interventions

Type	Name	Description
DEVICE	transcutaneous auricular vagus nerve stimulation	The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles). The dispositive is used every day at home, twice daily (during 30 minutes)
DEVICE	Placebo device	The intervention begins on the first day of chemotherapy and continues daily until 21 days after the end of chemotherapy (6 cycles). The dispositive is used every day at home, twice daily (during 30 minutes)

Timeline

Start date: 2025-04-30
Primary completion: 2028-06-30
Completion: 2028-09-30
First posted: 2025-02-10
Last updated: 2025-10-07

Locations

4 sites across 1 country: France

Source: ClinicalTrials.gov record NCT06817161. Inclusion in this directory is not an endorsement.